Transparency Market Research Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
Published Date 1-Sep-2014
74 Page Report
Buy Now
Request Sample
Press Release
Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Reveals Six Potential Late Stage Candidates, and Ten Late Stage Candidates: Transparency Market Research
Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com
Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market
REPORT DESCRIPTION
Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020 According to a new market report published by Transparency Market Research "Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market (Tedizolid Phosphate, Ceftolozane/Tazobactam, Ceftazidime/Avibactam, Amikacin Inhale, Plazomicin, and Synflorix) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" six phase III drugs would generate total revenue of USD 3.8 billion by 2020. Browse the full Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Report at http://www.transparencymarketresearch.com/hospital-acquired-pneumonia-drugs.html Hospital acquired infections also called as healthcare associated infections or nosocomial infections have raised serious concerns due to multidrug resistance shown by microorganisms. Multidrug resistant organisms are immune to the conventional antibiotics, hence very difficult to treat. Pneumonia accounts for over 22% of all the hospital acquired infections. Since hospital acquired pneumonia is mainly caused as a result of prolonged exposure to ventilator, it is also called as ventilator associated pneumonia. The infection is common in immunocompromised patients, post surgical infections, enteral feeding, and in elderly and infant patients. Various gram positive as well as gram negative bacteria are known to cause hospital acquired pneumonia. Major causative agents include methicillin resistant S. aureus (MRSA), multi drug resistant (MDR) P. aeruginosa, Klebsiella and Acinetobacter. Respiratory Syncytial Virus (RSV) is found to be a major causative agent of nosocomial pneumonia in new borne. Currently there are five investigational drugs and one vaccine in stage III clinical trials, while ten other candidates in early stage. Phase III candidates include Tedizolid phosphate and Ceftolozane/tazobactam by Cubist Pharmaceuticals, Ceftazidime/avibactam by AstraZeneca PLC, Amikacin inhale by Bayer Healthcare, Plazomicin by Achaogen, Inc. and Synflorix by GlaxoSmithKline. Majority of these drugs are expected to be launched by 2017. Analysis reveals that majority of the candidates in late stage are biological drugs. This indicates a paradigm shift from traditional antibiotic therapy to more sophisticated biological drug therapy. Aridis Pharmaceuticals hold a strong monoclonal antibody pipeline with four candidates for treatment of hospital acquired pneumonia which was acquired from Kenta Biotech in 2013. Growing drug resistance has been a major concern in hospitals globally. According to a report published by Centers for Disease Control and Prevention (CDC) in 2013 which considers the U.S. population for study, 63% of Acinetobacter is considered multi drug resistant. Methicillin resistant Staphylococcus aureus (MRSA) is one of the most hazardous organisms causing ventilator-associated pneumonia. CDC estimates that over 80,400 MRSA infections occurred in 2011, of which more than 11,000 patients died. Furthermore, World Health Organization (WHO) suggests that prevalence of nosocomial infections is higher in low and middle income countries. This suggests that the conditions are more alarming in these regions. In addition,
Transparency Market Research
2
Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market
rate of hospital acquired infections have been declining since recent past according to statistics published by Office National Statistics, U.K. Key companies in the market include Achaogen, Inc., Aridis Pharmaceutical, AstraZeneca PLC, Basilea Pharmaceutica Ltd., Bayer Healthcare, Cubist Pharmaceutical, GlaxoSmithKline, Meiji Seika Pharma Co., Ltd., Merck & Co., and Valneva SE. Get Sample Copy of Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market @ http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1881 Hospital Acquired Pneumonia Drug Pipeline is as follows: Global Hospital Acquired Pneumonia Drug Pipeline, Late Stage Candidates (Phase III)
•
Tedizolid phosphate
•
Ceftolozane/tazobactam
•
Ceftazidime/avibactam
•
Amikacin inhale
•
Plazomicin
•
Synflorix
Global Hospital Acquired Pneumonia Drug Pipeline, Early Stage Candidates (Phase II, Phase I and Preclinical Trials)
•
AR-101 or KBPA101
•
GSK 2189242A
•
BAL30072
•
MEDI4893
•
AR 301 or KBSA301
•
ME1100
•
V114
•
AR-104 or KBPA104
Transparency Market Research
3
Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market
• •
AR-201 or KBRV201 AR-401 or KBAB401
Browse the full Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Report at http://www.transparencymarketresearch.com/hospital-acquired-pneumonia-drugs.html
TABLE OF CONTENT
Chapter 1 Introduction 1.1 Report Description 1.2 Market Segmentation 1.3 Research Methodology 1.3.1 Secondary Research 1.3.2 Primary Research 1.4 List of Abbreviations 1.5 Assumptions
Chapter 2 Executive Summary 2.1.1 Hospital Acquired Pneumonia Phase III Candidates, Market Share, 2020 (Value %)
Chapter 3 Market overview 3.1 Introduction 3.1.1 Types of Nosocomial Pneumonia
Transparency Market Research
4
Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market
3.1.1.1 Bacterial pneumonia 3.1.1.2 Viral pneumonia 3.1.2 Epidemiology of hospital acquired pneumonia 3.1.3 Diagnosis of hospital acquired pneumonia 3.1.4 Treatment of hospital acquired pneumonia 3.2 Market Dynamics 3.2.1 Market Drivers 3.2.1.1 Rising drug resistance among infectious microorganisms increasing chances of hospital acquired infections 3.2.1.2 Inefficient sterilization and unhygienic conditions in low and middle income countries increasing prevalence of hospital acquired infections 3.2.1.2.1 Prevalence of hospital acquired infections in developed and developing countries 3.2.2 Market Restraints 3.2.2.1 Government scrutinizing hospital policies to curb hospital-acquired infections 3.2.3 Market Opportunities 3.2.3.1 Promising future for vaccines in the nosocomial pneumonia market 3.2.3.2 Potential for research in vaccine development for causative agents other than S. pneumonia 3.3 Event Impact Analysis 3.3.1 Event Impact Analysis: Hospital Acquired Pneumonia Market 3.4 Value Chain Analysis 3.4.1 Value Chain Analysis
Transparency Market Research
5
Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market
3.5 Porter’s Five Forces Analysis for the Global Hospital Acquired Pneumonia Drugs Market 3.5.1 Bargaining Power of Suppliers 3.5.2 Porter’s Five Forces Analysis: Global Hospital Acquired Pneumonia Market 3.5.3 Bargaining Power of Buyers 3.5.4 Threat of Substitutes 3.5.5 Threat of New Entrants 3.5.6 Competitive Rivalry 3.6 Market Analysis of Major Drugs and Vaccines for Hospital Acquired Pneumonia 3.6.1 Revenue trend of major branded drugs and vaccines in nosocomial pneumonia market (USD Million) Request for customization of this report http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1881 Chapter 4 Hospital Acquired Pneumonia, Pipeline Analysis 4.1 Introduction 4.2 Late Stage (Phase III) 4.2.1 Tedizolid phosphate 4.2.1.1 Global Tedizolid Phosphate Market Revenue, 2017 – 2020 (USD million) 4.2.2 Ceftolozane/Tazobactam 4.2.2.1 Global Ceftolozane/Tazobactam Market Revenue, 2017 – 2020 (USD million) 4.2.3 Ceftazidime/Avibactum 4.2.3.1 Global Ceftazidime/Avibactam Market Revenue, 2017 – 2020 (USD Million)
Transparency Market Research
6
Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market
4.2.4 Amikacin Inhale 4.2.4.1 Global Amikacin Inhale Market Revenue, 2016 – 2020 (USD Million) 4.2.5 Plazomicin 4.2.5.1 Global Plazomicin Market Revenue, 2017 – 2020 (USD Million) 4.2.6 Synflorix Vaccine 4.2.6.1 Global Synflorix Market Revenue, 2012 – 2020 (USD Million) 4.3 Early Stage (Phase I and II) 4.3.1 BAL30072 4.3.2 MEDI4893 4.3.3 AR-301 or KBSA301 4.3.4 AR-101 (or KBPA101) and AR-104 (or KBPA104) 4.3.5 AR-201 (or KBRV201) 4.3.6 AR-401 (or KBAB401) 4.3.7 ME1100 4.3.8 GSK 2189242A 4.3.9 V114 4.3.10 IC43
Chapter 5 Global Pipeline Review of Hospital Acquired Pneumonia Drugs Market, by Geography 5.1 Introduction
Transparency Market Research
7
Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market
5.2 North America 5.3 Europe 5.4 Asia Pacific 5.5 Rest of the World
Chapter 6 Recommendations 6.1 Research and development for biological drugs 6.2 Mergers, acquisitions and strategic agreements Browse All Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
Chapter 7 Company Profiles 7.1 Achaogen, Inc. 7.1.1 Company Overview 7.1.2 Financial Overview 7.1.3 Product Portfolio 7.1.4 Business Strategies 7.1.5 Recent Developments 7.2 Aridis Pharmaceuticals 7.2.1 Company Overview 7.2.2 Financial Overview
Transparency Market Research
8
Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market
7.2.3 Product Portfolio 7.2.4 Business Strategies 7.2.5 Recent Developments 7.3 AstraZeneca plc 7.3.1 Company Profile 7.3.2 Financial Overview 7.3.3 Product Portfolio 7.3.4 Business Strategies 7.3.5 Recent Developments 7.4 Cubist Pharmaceuticals, Inc. 7.4.1 Company Overview 7.4.2 Financial Overview 7.4.3 Product Portfolio 7.4.4 Business Strategies 7.5 Meiji Seika Pharma Co. Ltd. 7.5.1 Company Overview 7.5.2 Financial Overview 7.5.3 Product Portfolio 7.5.4 Business Strategies 7.5.5 Recent Developments
Transparency Market Research
9
Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market
7.6 Merck & Co. Inc. 7.6.1 Company Overview 7.6.2 Financial Overview 7.6.3 Product Portfolio 7.6.4 Business Strategies 7.6.5 Recent Developments 7.7 Sanofi 7.7.1 Company Overview 7.7.2 Financial Overview 7.7.3 Product Portfolio 7.7.4 Business Strategies 7.7.5 Recent Developments 7.8 GlaxoSmithKline, Inc. 7.8.1 Company Overview 7.8.2 Financial Overview 7.8.3 Product Portfolio 7.8.4 Business Strategies 7.8.5 Recent Developments 7.9 Valneva SE 7.9.1 Company Overview
Transparency Market Research
10
Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market
7.9.2 Financial Overview 7.9.3 Product Portfolio 7.9.4 Business Strategies 7.9.5 Recent Developments Browse Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Report with Full TOC at http://www.transparencymarketresearch.com/hospital-acquired-pneumonia-drugs.html
About Us
Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forwardlooking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Contact Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/
Transparency Market Research
11